anonymous
Guest
anonymous
Guest
Q2 results were laughable…$6.7M???? That’s it? Crack staff of oncology reps we have here…only 175 prescribers? What is that like, 2 to 3 prescribers per territory? We are getting beat by drugs with zero data in our indication. Strong share of voice in R/R RCC? No kidding…no one else is promoting in that space.
Earnings call was a mess. No wonder our stock is dying. What a mess.
Earnings call was a mess. No wonder our stock is dying. What a mess.